The undesired presence of GM plants outside of cultivation is one of main concerns for the ecological risk assessment and regulation of GM plants, and how long transgenic volunteers can persist in the nature remains unknown. We conducted two long-term coexistence experiments of Bt-transgenic insect-resistant crops in populations of their wild relatives, using Bt-transgenic oilseed rape (Brassica napus) in wild mustard (B. juncea) populations from 2012 to 2019, and Bt-transgenic rice (Oryza sativa) in wild rice (O. rufipogon and O. minuta) populations from 2013 to 2019. Transgenic oilseed rape volunteers survived only in the 2012 winter, because it is a spring variety and not be resistant to cold climate and competition from weeds. Transgenic rice was not survived because of its low competitive ability compared to wild rice, but survived five years in one population of wild rice O. minuta who could not tolerant to cold temperature. Our results indicated that transgenic volunteers can persist in the wild populations under natural conditions, but the fate of transgenic volunteers in the nature depends on whether the growth environment is favorable, and they could not disperse over its niche or "tolerance zone".
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.plaphy.2022.07.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Electroconvulsive shock and transcranial magnetic stimulation do not alter the survival or spine density of adult-born striatal neurons.
PLoS One
January 2025
Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.
Adult neurogenesis has most often been studied in the hippocampus and subventricular zone-olfactory bulb, where newborn neurons contribute to a variety of behaviors. A handful of studies have also investigated adult neurogenesis in other brain regions, but relatively little is known about the properties of neurons added to non-canonical areas. One such region is the striatum.
View Article and Find Full Text PDFPFKFB3 decreases α-ketoglutarate production while partial PFKFB3 knockdown in macrophages ameliorates arthritis in tumor necrosis factor-transgenic mice.
Int Immunopharmacol
January 2025
Department of Immunology, Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, China. Electronic address:
Objective: Aberrant 6-phosphofructo-2kinase/fructose-2,6-bisphoshatase 3 (PFKFB3) expression is tightly correlated with multiple steps of tumorigenesis; however, the pathological significance of PFKFB3 in macrophages in patients with rheumatoid arthritis (RA) remains obscure. In this study, we examined whether PFKFB3 modulates macrophage activation and promotes RA development.
Method: Peripheral blood mononuclear cells (PBMCs) from patients with RA, THP-1 cells, and bone marrow-derived macrophages from conditional PFKFB3-knockout mice were used to investigate the mechanism underlying PFKFB3-induced macrophage regulation of RA.
Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies.
Alzheimers Res Ther
October 2024
Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Article Synopsis
- SHR-1707 is a novel monoclonal antibody designed to target Aβ, aiming to reduce plaque formation in potential Alzheimer's disease treatment; preclinical tests in mice have shown promising results in decreasing Aβ deposits.* -
- Two phase 1 clinical trials were conducted to assess SHR-1707 in healthy adults in China and Australia, focusing on safety, tolerability, and how the drug behaves in the body (pharmacokinetics and pharmacodynamics) after a single intravenous dose.* -
- Results indicated that SHR-1707 was generally well-tolerated with mostly mild adverse effects reported; the drug showed a dose-dependent increase in plasma Aβ levels, with similar safety and body response profiles observed in both younger and
Phase 1 Safety and Pharmacokinetics Study of TAVO101, an Anti-Human Thymic Stromal Lymphopoietin Antibody for the Treatment of Allergic Inflammatory Conditions.
J Clin Pharmacol
August 2024
Tavotek Biotherapeutics, 727 Norristown Road, Lower Gwynedd, PA, USA.
TAVO101 is a humanized anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody under clinical development for the treatment of atopic dermatitis (AD) and other allergic inflammatory conditions. The crystallizable fragment region of the antibody was engineered for half-life extension and attenuated effector functions. This Phase 1, double-blinded, randomized, placebo-controlled study assessed the safety, tolerability, pharmacokinetics, and immunogenicity of TAVO101 in healthy adult subjects in seven ascending dose cohorts.
View Article and Find Full Text PDF11β hydroxysteroid dehydrogenase type 1 transgenic mesenchymal stem cells attenuate inflammation in models of sepsis.
Front Bioeng Biotechnol
July 2024
Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.
Background: Human bone marrow mesenchymal stem cell (MSC) administration reduces inflammation in pre-clinical models of sepsis and sepsis-related lung injury, however clinical efficacy in patients has not yet been demonstrated. We previously showed that Alveolar Macrophage (AM) 11β-hydroxysteroid dehydrogenase type-1 (HSD-1) autocrine signalling is impaired in critically ill sepsis patients, which promotes inflammatory injury. Administration of transgenic MSCs (tMSCs) which overexpress HSD-1 may enhance the anti-inflammatory effects of local glucocorticoids and be more effective at reducing inflammation in sepsis than cellular therapy alone.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!